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The immunomodulatory activity of an Indian neutraceutical spice, saﬀron (Crocus sativus) was studied on Th1 and Th2 limbs of
the immune system. Oral administration of alcoholic extract of Crocus sativus (ACS) at graded dose levels from 1.56–50mg/kg p.o.
potentiated the Th2 response of humoral immunity causing the signiﬁcant increases in agglutinating antibody titre in mice at a
doseof6.25mg/kgandanelevationofCD19+ BcellsandIL-4cytokine,asignaturecytokineofTh2 pathway.Appreciableelevation
in levels of IgG-1 and IgM antibodies of the primary and secondary immune response was observed. However, ACS showed no
appreciable expression of the Th1 cytokines IL-2 (growth factor for CD4+ Tc e l l s )a n dI F N - γ (signature cytokine of Th1 response).
A signiﬁcant modulation of immune reactivity was observed in all the animal models used. This paper represents the selective
upregulation of the Th2 response of the test material and suggests its use for subsequent selective Th2 immunomodulation.
1.Introduction
Complementary and alternative medicines (CAM), together
with traditional medicines, have attracted much attention
[1]. The lesson to be learned and eventually put into practice
concerns a wider approach to a search for useful drugs and
applicableCAMproductsfromdiverseterrestrialsources[2–
5]. There is even room to consider a diverse array of complex
derivatives from certain natural products [6–9]. One theory
of immune regulation involves homeostasis between T-
helper 1 (Th1) and T-helper 2 (Th2)a c t i v i t y .S e v e r a ln u t r i -
ents and hormones measurably inﬂuence Th1/Th2 balance,
including plant sterols/sterolins, oligodeoxynucleotides, pro-
biotics, estrogen, and the minerals like zinc. In the present
study we report the selective upregulation of the Th-2
response by, an Indian neutraceutical spice, saﬀron—Crocus
sativus (Figure 1).
Th1 cells follow the type-1 pathway (“cellular immu-
nity”) to eliminate viruses and other intracellular pathogens,
ﬁght cancerous cells, and stimulate delayed-type hypersensi-
tivity (DTH) reactions. Th2 cells drive the type-2 pathway
(“humoral immunity”) and are responsible for the upreg-
ulation of the antibody production to ﬁght extracellular
pathogens; it is the type 2 dominance which is responsible
for the tolerance of xenografts and of the fetus during
pregnancy. T helper (Th) lymphocyte balance (Th1/Th2) is
crucial in orchestrating the appropriate cytokine responses
and hence remains as one of targets for immunomodulation
and immune-based therapies. Th1-type cytokines (IFN-
γ, IL-2) promote cell-mediated immunity and Th2-type
cytokines (IL-4, 10) are responsible for humoral immunity
leading to increased IgE. Over activation of either pattern
can cause disease, and either pathway can downregulate the
other. Hence, the optimal immunotherapy should restore or
maintain a well balanced Th1 and Th2 response, suited to
the immune challenge [10]( Figure 2). Saﬀron is a native
of south Europe and is cultivated in Spain, France, Italy,
Greece, Turkey, Persia, India, and China. In India it is
one of the natural and delicious cash crop of Kashmir
(Jammu and Kashmir state). It has been growing here since
centuries and is cultivated on a commercial scale in the
vast ﬁeld in the Karewa lands of Pampore (5,300ft above
sea level). Botanically, saﬀron (Crocus sativus)b e l o n g st oa
family of Iridacaee, is a small perennial herb with globular
corms which attain a size of about 4 to 5cm in diameter
at maturity. Propagation of the saﬀron plant is through
corms and is harvested from the dried, dark red stigmas of
Crocus ﬂowers.Since its tiny ﬁlamentsmust be painstakingly
harvested by hand, it is no surprise that it ranks as the
world’s most expensive spice. Saﬀron has been widely used2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Crocus ﬂowers and their reddish-orange stamens which are plucked, then dried.
throughout the world due to its innumerable eﬀect on the
human body as a spice and as a folk medicine, to treat the
nervous system (insomnia, paralysis), the respiratory system
(asthma, colds), the cardiovascular system (heart disease),
thedigestivesystem(stomachdisorders,ﬂatulence,colic,and
ailmentssuchasscarletfever,smallpox,gout,andeyedisease.
It has been also used as an aphrodisiac, antispasmodic,
and expectorant [11]. Modern pharmacological studies have
demonstrated Crocus sativus or its active constituents to have
anti-inﬂammatory [12], antioxidant [13, 14], hypolipidemic
[15], insulin-resistance reducing [16], and hypoglycemic
[17]e ﬀects. Modulation of immune responses is, possibly,
one most important factor responsible for these activities.
Immune homeostasis is dependent on Th1/Th2 equilibrium.
Shift towards Th1 or Th2 initiates abnormal condition
related to many diﬀerent disorders. As literature suggests
saﬀron or its active constituents to have anti-inﬂammatory,
antioxidant, hypolipidaemic properties, and so forth, these
disorders are all related to proinﬂammatory Th1 pathway
activation and their inhibition suggests Th2 upregulation
induction by saﬀron. Th2 upregulation inhibits the hyper-
activation of Th1 pathway thus balancing the Th1/Th2
paradigm.
2.MaterialsandMethods
2.1. Plant Material. The orange-red colored threelobed fresh
stigmas of C. sativus Linn. were collected directly from
farmers ﬁeld of Srinagar, Jammu, and Kashmir, India and
authenticated by Dr B. K. Kapahi (Indian Institute of
Integrative Medicine (CSIR), Jammu and Kashmir, India).
The collected stigmas (saﬀron) were dehydrated in hot air
dryer at 40 ± 5◦C( o n eb a t c h )a n dw a ss t o r e da t4 ◦Cu n d e r
nitrogen for further experiments.
2.2. Preparation of Aqueous Extract from Dried Stigmas. The
dried stigmas (10g.) were extracted with deionized water
under ultrasonic extractor (Sonics, Model VC 750) using
amplitude 65% for 5 minutes without using pulse, for three
times with maceration for complete extraction. The extract
solution was ﬁltered and freeze-dried (Telstar, Lyobeta 35)
whenitaﬀordedabrightredcolouredshiningpowder(6.5g)
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Figure 2: Cytokine-mediated diﬀerentiation of Th1/Th2 cells.
Undiﬀerentiated naive T cells secrete speciﬁc cytokines after
antigenicstimulusthatpolarizes,ﬁrstintonullT-helpercells(Th0),
then into Th1or Th2 cells.
which was stored at −4◦C under nitrogen atmosphere for
further experiments.
2.3. Column Chromatography for Isolation of Crocin-1 and
Crocin-2. Marker compounds of the obtained extract were
isolated by silica gel column chromatography (extract:
silica gel ratio 1:20, elution solvent system (isocratic):
ethylacetate:methanol:water 100:16.5:13.5). The frac-
tions were pooled according to TLC on solvent system
EtOAc:MeOH:H2O (100:16.5:13.5) to aﬀord crocin-1
(all-trans-crocetindi(β-D-gentiobioside ester)) and crocin-2
(all-trans-crocetin-β-D-gentiobiosyl-β-D-glucosyl ester) for
the standardization of the extract [18].
2.4. HPLC Fingerprint for Analyzing the Saﬀron Extract.
HPLC ﬁngerprint was used to analyze the saﬀron extract.Evidence-Based Complementary and Alternative Medicine 3
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Figure 3: HPLC proﬁle of water extract of ACS at 440nm.
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Figure 4: Schematic representation of experimental procedure.
Balance (GH-252, MAX 210 g, d = 0.1mg, produced by
A & D Company Limited) and PDA-detector (water’s 996
photodiode array detector) were used. The waters HPLC
systemequippedwithpump(waters600quaternarygradient
pump) with waters 717 plus automated sample injector
facility, and empower 2 software. The column was stainless-
steel column Lichrosphere 100-RP-18e (250mm × 4mm
× 5μm; Merck Co., Ltd). The chromatographic conditions
include mobile phase, the linear gradient from 10% to
100% methanol in water containing 1% acetic acid in
50min. 10 minutes equilibration. The solvent ﬂow rate was
1.0ml/min and the sample injection volume 10μl (concn.
2mg saﬀron/ml., Millipore Millex Nylon (0.45μm) ﬁlter
was used for ﬁltration) with PDA detector at wavelength of
440nm (for Crocin). Crocin-1 eluted at 37.446min while
crocin-2 at 39.903min (Figure 3).
2.5.Animals. MaleBalb/cmice10–12weekoldandweighing
20–24 grams obtained from animal house of Indian Institute
of Integrative Medicine, Jammu were taken up in groups
of six and employed for the study. These animals were
maintained at a room temperature of 20 ± 2◦Cw i t h1 2 h
light/dark cycle with free access to pellet food and water.
According to ethical regulations on animal research all
animals used in experimental work received humane care.
Animals were housed and maintained following standard
guidance as found in Government of India guidelines [19].
The study protocol was approved by Institutional Animal
Ethics Committee. Ten experimental groups comprising of
six animals each were employed for the study including
an a ¨ ıve control group, sensitized control group, groups
receiving standards, and drug-treated groups (receiving test
drugs at graded concentration).
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Figure 5: Eﬀect of ACS on humoral immunity as assessed by PFC
assay.
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Figure 6: Eﬀect of ACS on T lymphocytes (CD4+,C D 8 +,C D 3 +)i n
normal Balb/c mice.
2.6. Drugs. Test drug was prepared in distilled water and
was administered orally daily once a day for the duration
of experiment at 1.56, 3.12, 6.25, 12.5, 25, and 50mg/kg
p.o. dose. The broad range of oral dosage was taken up
to get dose reponse and to determine the dose with most
signiﬁcant eﬀect. Preliminary study with the extract (data
not shown) showed the signiﬁcant eﬀect to be at the doses
of 6.25 and 12.5mg/kg p.o. Keeping this in mind we carried
out studies taking two lower and two higher doses along with
the eﬀective doses. Levamisole at 2.5mg/kg per oral dose
was used as positive control and Cyclosporin-A was used
as immunosuppressive agent at 5mg/kg per oral dose. The
standards were also freshly prepared and administered orally
during the experimental duration.
2.7. Antigenic Stimulus. Fresh sheep red blood cells (SRBC)
were collected aseptically from the jugular vein of sheep and4 Evidence-Based Complementary and Alternative Medicine
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Figure 8: Eﬀect of ACS on Th1 cytokine (IL-2, IFN-gamma)
expression in whole blood of normal Balb/c mice.
stored in cold sterile Alsever’s solution These were washed
three times with pyrogen free sterile saline (0.9% NaCl w/v)
and adjusted to the concentration of 5 × 109 cells/ml for
immunization and challenge at the required time schedule.
2.8. Eﬀect on General Behavior and Maximum Dose Tolerance
in Mice. The acute oral toxicity studies were carried out after
approval from the Institutional Animal Ethics Committee
following OECD (Organization for Economic Cooperation
andDevelopment)Guidelines423[20].Thetestmaterialwas
found to be safe up to 2000mg/kg with no adverse eﬀects on
general behavior in treated BALB/c mice.
2.9. Humoral Antibody Response to SRBC. Groups of 6 mice
each were immunized by injecting 0.2ml of 5×109 SRBC/ml
intraperitoneally (i.p.) on day 0 and challenged 5 days
later on day 6 by injecting an equal volume of SRBC
intraperetoneally. Blood samples were collected on day 7
for antibody titre. Haemagglutination antibody titres were
determinedfollowingthemicrotitrationtechniquedescribed
by Nelson and Mildenhall [21]. The value of the highest
serum dilution causing visible haemagglutination was taken
as a titre. BSA-saline alone served as a control.
2.10. Delayed Type Hypersensitivity Response (DTH). The
method of Doherty [22] was followed. 200μlo f5×
109 SRBC/ml were injected intraperitoneally to immunize
the mice on Day 0. Six days later the thickness of the left
hind food was measured with a spheromicrometer (0.01mm
pitch) and was considered as a control. The mice were
then challenged by injecting the same amount of SRBC
intradermally into the left hind footpad. The foot thickness
was measured again after 24h.
2.11. Plaque Forming Cell (PFC) Assay. Mice were immu-
nized by an injection of 0.2ml of 10% (v/v) suspension of
SRBC in normal saline. Five days later the animals were
sacriﬁced and their spleen was removed aseptically. A single
cell suspension of an individual spleen was prepared in
RPMI 1640 medium and viability was checked by trypan
blue dye exclusion test. Cell concentration was adjusted to
2 × 107 cells/ml in RPMI 1640. To 0.1ml of this suspension,
0.3ml of 5% SRBC suspension, 0.lml of guinea pig serum,
and 0.5ml of RPMI 1640 medium were added. A 150μl
quantity of this mixture was added to each Cunningham’s
chamber. The chambers were sealed with paraﬃnw a xt o
prevent dehydration. These chambers were incubated for
60 to 90min at 37
◦C in incubator. Plaques in SRBC lawn
were enumerated using an inverted microscope. Each plaque
represented a product of an individual antibody forming cell
[23].
2.12. Lymphocyte Immunophenotyping. Immunizatin of
Balb/c mice was carried out by injecting 200μlo f
5 × 109 SRBC/ml i.p. Drug administration was carried
out for 5 days. Same amount of SRBC was then injected
into the mice for the challenge and blood was collected
after 48h of challenge in heparinised tubes from retroorbital
plexus (Figure 4). Lymphocyte subsets were measured
by immunoﬂuorescent antibody staining of whole
blood and subsequently analyzed using two color ﬂow
cytometry. Murine monoclonal antibodies conjugated to a
ﬂuorochrome and directed against receptors CD3, CD4 and
CD8 were used for the study. FITC (Fluoroisothiocyanate)
labelled antimouse CD4 monoclonal antibody that reacts
with the CD4 surface antigen expressed on MHC class II
restricted T cells that includes most helper cells and FITC
(Fluoroisothiocyanate) labelled CD8 monoclonal antibody
that reacts with CD8 diﬀerentiation antigen present on
MHC class-I restricted T cells were used to determine the
percentage of CD4+ and CD8+ T cells in control and treated
groups of animals. For the B cell counts (TH2 response)
CD19+ antimouse monoclonal antibody was used whichEvidence-Based Complementary and Alternative Medicine 5
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Figure 9:EﬀectofACSonTh2cytokine(IL-4)expressioninwhole
blood of normal Balb/c mice.
was labeled with the Phycoerythrin ﬂourochrome. These
ﬂuorochrome-labeled monoclonal antibodies were added
directly to 100μl of whole blood, which was then lysed using
whole blood lysing reagent (BD Biosciences). Following
the ﬁnal centrifugation, samples were resuspended in
phosphate-buﬀered saline (pH, 7.4) and analyzed directly on
the ﬂow cytometer (LSR, BD Biosciences) using Cell Quest
Pro Software (BD Biosciences) [24, 25].
2.13. Intracellular Cytokine Estimation (Th1 and Th2 Cy-
tokines). The blood was collected in heparinised tubes
from retroorbital plexus as mentioned above. Fluoroisothio-
cyanate, FITC-labeled antimouse IL-2 monoclonal antibody
and Phycoerythrin (PE)-labeled IL-2 monoclonal antibodies
were used in one set and Fluoroisothiocyanate, FITC-labeled
antimouse labeled IFN-γ monoclonal antibody was used
in the other set of experimentation, however, for the Th2
response PE labeled IL-4 was used [24, 25].
2.14. Evaluation of Primary Ig-G and Ig-M Antibody. The
analysis of subsets namely Ig-G and Ig-M was performed on
peripheral blood. Brieﬂy, mice were bled at required time
schedules and 50μL of blood was added to falcon tubes (BD
Biosciences) containing diﬀerent antimouse immunolabeled
monoclonal antibodies for Ig-G1 and Ig-M. After mixing
and incubating at room temperature for 30 minutes in the
dark, FACS lysing solution was added. The samples were
incubated for 10 minutes at room temperature, followed by
centrifugation. The cells were washed and enumeration of
lymphocytes subsets was done using ﬂow cytometer. 10,000
events were collected to analyze Ig-G and Ig-M expression
[24, 25].
2.15. Statistical Analysis. The results were expressed as
Mean ± SEM of three independent experiments. Results are
presented as fold increase/decrease values compared with the
untreated control. Statistical signiﬁcance was determined by
Student’s t-test, comparing the experimental group to the
control group.
Table 1: Immunomodulatory activity of ACS on Humoral (Anti-
body titre) and cell-mediated immune response (CMI) in normal
Balb/c mice.
Test material
Dose
mg/kg
p.o.
Humoral response
antibody titre
mean ±S.E.
CMI response
foot thickness
(mm) 24h
mean ±S.E.
Control — 6.18 ±0.36 0.68 ±0.06
ACS 1.56 7.03 ±0.11
(13.91↑)
0.74 ±0.28
(8.82↑)
ACS 3.12 7.10 ±0.28
(14.88↑)
0.75 ±0.38
(10.29↑)
ACS 6.25 8.03 ±0.43
∗∗
(29.93↑)
0.78 ± 0.30
∗
(14.70↑)
ACS 12.50 8.01 ±0.56
∗∗
(29.61↑)
0.77 ±0.13
(13.23↑)
ACS 25.00 7.63 ±0.48
∗∗
(23.46↑)
0.76 ±0.43
(11.76↑)
ACS 50.00 7.40 ± 0.56
∗
(19.74↑)
0.73 ±0.48
(7.35↑)
Levamisole 2.5 8.39 ±0.16
∗∗
(35.76↑)
0.88 ±0.18
∗∗
(29.14↑)
Cyclosporine 5.00 3.92 ±0.31
∗∗
(36.56↓)
0.42 ±0.13
∗∗
(38.23↓)
Value in parentheses signify percentage activity in agglutinating antibody
titre and CMI Response
↓:P ercentDecrease,↑:P ercentIncrease
n = 6,
A l lv a l u e sa r es h o w na sM e a n±S.E.
P-value:∗ <. 01;∗∗ <. 001,
P-values were calculated by Student’s t.
3. Results
3.1. Eﬀe c to nG e n e r a lB e h a v i o u ra n dM a x i m u mD o s eT o l e r -
anceinMice. MicetreatedwithACSatamaximumoraldose
of 2000mg/kg did not show any diﬀerence in gross general
behaviour compared with the control group of animals
that were administered only the vehicle. No mortality was
observed over an observation period of 7 days.
3.2. Humoral Antibody Response to SRBC. As indicated in
Table 1 ACS modulated the humoral immune response and
showed a dose-dependent increase in antibody titres. Signif-
icant increase in antibody titres was observed at 6.25mg/kg
(P<. 001), under the same conditions, signiﬁcantly higher
antibody titres were observed with Levamisole at dose of
2.5mg/kg (P<. 001). The immunomodulatory activity of
ACS at 6.25mg/kg observed was 29.93%.
3.3. Delayed Type Hypersensitivity Response (DTH). The
DTH response showed by ACS is reﬂected in the CMI
Response in Table 1. ACS when administered orally showed
a dose-dependent increase where maximum eﬀect was
observed at 6.25mg/kg p.o. (P<. 01) where the immun-
omodulatory eﬀect on the potentiating side was found to
be 14.70%. Levamisole that was used as a positive standard
at dose of 2.5mg/kg resulted in higher immunomodulating6 Evidence-Based Complementary and Alternative Medicine
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Figure 10: Flow cytometric representation showing eﬀect of ACS on Ig-G1 and Ig-M. Cells were labeled with Ig-G1 (FITC-conjugated
monoclonal antibody) and Ig-M (PE-conjugated monoclonal antibody) and analysed in ﬂowcytometer using cell-quest software.
activity (P<. 001) with the percentage increase of 29.14%
in normal Balb/c mice, however, Cyclosporine A markedly
suppressed paw oedema where a decrease of 38.23% was
observed.
3.4. PFC Assay. The eﬀect of ACS on the number of PFC
in the spleen is shown in Figure 5. The maximum increase
in the PFC assay in ACS treated groups at 6.25mg/kg was
observed on day 5 after the immunization in comparison
with control animals. Levamisole (2.5mg/kg) used as a
positive control produced signiﬁcant stimulation in the PFC
assay.
3.5. Lymphocyte Immunophenotyping. The animals treated
withACSat6.25mg/kgp.o.dose-dependenteﬀectof33.26%
for CD4+ and 17.40% for CD8+ T cells and 32.90% of CD4+
and17.16%ofCD8+ Tcellsatperoraldoseof12.5mg/kg.In
the sensitized control group the percentage of T lymphocyte
subsets observed was 26.25% and 19.66% for CD4+ and
CD8+ T cells. Cyclosporin-A a standard immunosuppressive
T cell inhibitor at 5mg/kg oral dose inhibited both CD4+
and CD8+ T cells showed 18.61% of CD4+ and 10.29% of
CD8+ T cells. Levamisole potentiated both CD4+ and CD8+
T cell counts, the increase observed was 37.30% and 21.50%
for CD4+ and CD8+ T lymphocyte subsets.
As indicated in Figure 6, ACS showed a dose-dependent
increaseinCD3+ Tcellsubsets,whichrepresentthetotal“T”
cell population. ACS at 6.25mg/kg dose showed 43.70% of
CD3+ T cell counts and 38.79% at 12.50mg/kg. Cyclosporin
inhibited CD3+ T lymphocytes and Levamisole signiﬁcantly
increased the total lymphocyte counts where 24.90% was
observed for Cyclosporin and 52% was observed for Lev-
amisole.
The eﬀect of test material on CD19+B cell counts;
representing the B cell population of the Th2 response
was studied in normal Balb/c mice (Figure 7). Test mate-
rial administration at 6.25mg/kg resulted in a signiﬁcant
increase in CD19+B cells (P<. 001) where the percentage
observed was 53%, however, for the sensitized control group
31.40% of B lymphocytes was observed. Cyclosporin-A
administration resulted reduction in B cell counts (P<. 001)
as compared to control indicative of immune suppression
and Levamisole signiﬁcantly increased the B cell types of the
Th2 response.
3.6. Eﬀect of ACS on Th1 and Th2 Cytokines. To determine
immunomodulating eﬀect on Th1-Th2 balance, selected
cytokine levels produced by Th1 and Th2 subsets were
measured in vivo using ﬂow cytometry.
3.7. Th1 Cytokines (IFN-Gamma and IL-2). Oral adminis-
tration of ACS at speciﬁc doses showed a signiﬁcant dose
dependent upregulation of Th1 cytokine IL-2, growth factor
forCD4+Tcellsat the oral dosage of6.25mg/kg as compared
to sensitized control. (P<. 001), percent IL-2 expression
observed was 18.60% for ACS however in sensitized controlEvidence-Based Complementary and Alternative Medicine 7
group it was evaluated to be 13.63%., but for IFN-γ no
signiﬁcant increase was observed. Levamisole signiﬁcantly
upregulated IFN-γ production, which was observed to be
12.46%. Interestingly, IFN-γ was downregulated at 25 and
50mg/kg p.o dose (Figure 8) in which the percentages
dropped to 5.90% and 5.20%.
3.8. Th2 Cytokine (IL-4) Expression. A signiﬁcant eﬀect of
ACS was observed on IL-4 levels as compared with sensitized
control, signiﬁcant higher IL-4 levels were observed for
Levamisole (P<. 001). At 6.25mg/kg and 12.50mg/kg the
IL-4 expression was observed to be 19.10% and 17.40%,
when compared to sensitised control in which 12.08% of IL-
4 was observed. The increase in expression levels of IL-4 by
ACS can be compared to Levamisole in which 21.30% of IL-
4s e c r e t i o nw a so b s e r v e d( Figure 9). This suggests ACS to
possess selective modulating property of Th1-Th2 balance of
the immune system.
3.9. Evaluation of Primary Ig-G and Ig-M Antibody Expres-
sion. Elevation in levels of IgG-1 and IgM antibodies of the
primary and secondary immune response was observed in
ACS treated groups (Figure 10).
4. Discussion
Many herbal preparations alter immune function and
display an array of immunomodulatory eﬀects. In vari-
ous in vitro and in vivo studies, herbal medicines have
been reported to modulate cytokine secretion, histamine
release, immunoglobulin secretion, class switching, cellular
coreceptor expression, lymphocyte expression, phagocytosis,
a n ds oo n[ 26, 27]. Modulation of the Th1/Th2 balance
by administration of recombinant cytokines or cytokine
antagonists alters the outcome of the diseases [28]. However,
their clinical eﬃcacy has been limited and has associated
complications [29, 30]. The trends indicate that there is an
utmost need for orally active nonpeptide compounds that
can modulate Th1/Th2 balance [31]. In the present study,
we report that “ACS” dose-dependently potentiates the DTH
reaction induced by SRBC. DTH is a part of the process
of cell-mediated immune response and requires the speciﬁc
recognition of a given antigen by activated T lymphocytes,
which subsequently proliferate and release cytokines. These
in turn increase vascular permeability, induce vasodilatation,
macrophage, and activation, promoting increased phago-
cytic activity [32]. Increase in DTH reaction in mice
in response to antigen revealed the stimulatory eﬀect of
A C So nTl y m p h o c y t e sa n da c c e s s o r yc e l lt y p e sr e q u i r e d
for the expression of reaction [33]. Helper T (Th) cells
are a crucial component of the adaptive immune system
and are of fundamental importance in orchestrating the
appropriate response to pathogenic challenge. They fall
into two broad categories deﬁnned by the cytokines each
produces. Th1 cells produce interferon-gamma (IFN-γ)
and are required for selective immunity to intracellular
bacteria, viruses, and protozoa whereas Th2 produce IL-
4 and are required for optimal antibody production to
T-dependent antigens. Functionally, Th1 lymphocytes are
associated with inﬂammation and cell-mediated responses,
whereas Th2 cells provide help to B cells and so are linked
with antibody production. Infections that can be cleared
by type 1 responses include mycobacterial infections such
as tuberculosis and, Leishmania major, and viruses such
as inﬂuenza; Th1 cells are also associated with autoim-
mune diseases and graft rejection. Th2 responses, on the
other hand, give protection against helminths, certain viral
infections (e.g., measles) and are strongly associated with
allergy. The present study indicated that ACS showed
a dose-dependent increase in the T cells-mediated DTH
reaction in mice (Table 1). This showed its potentiating
eﬀect “T” lymphocytes [34]. Evidence that lends support
to the hypothesis of T-lymphocytes potentiation is the
signiﬁcant potentiating eﬀect of ACS on CD4+ and CD8+ T
cells (Figure 5). T Cells expressing CD4 are increased when
there is a general expansion due to active immunological
activity of the T cell lymphocyte subsets. Cytokines play
important roles at diﬀerent stages of the immune response,
and indeed are usually multifunctional. For example, with
suﬃcient antigenic stimulus, IFN-γ and IL-2 are important
for diﬀerentiation and proliferation of Th1 cells whereas
later their presence serves to enhance apoptosis of repeatedly
stimulated eﬀector cells. The Th1 and Th2 proliferation
rates are simple functions of the concentrations of the
growth factors IL-2 and IL-4, as well as of IFN-γ.A C S
induced a dose related upregulation of IL-2 (interleukin-2)
production by CD4+ T cells (Figure 7). IL-2 is secreted by
stimulated helper T cells and cytotoxic T cells. It promotes
proliferationand diﬀerentiation of additional CD4+ cells, B
cells, and activates macrophages. But when compared to
Levamisole (positive standard) IL-2 and IFN-γ were not
signiﬁcantly upregulated. The humoral immunity involves
interaction of B cells with the antigen and their subsequent
proliferation and diﬀerentiation into antibody-secreting
plasma cells. Antibody functions as the eﬀector of the
humoral response by binding to antigen and neutralizing
it or facilitating its elimination by cross-linking to form
clusters that are more readily ingested by phagocytic cells. To
evaluate the eﬀect of ACS on humoral response, its inﬂuence
was tested on sheep erythrocyte-speciﬁc haemagglutination
antibody titre in mice. Cyclosporin at a dose of 5mg/kg,
p.o., showed signiﬁcant inhibition in antibody titre response,
whileACSwasfoundtosigniﬁcantlyenhancetheproduction
of circulating antibody titre. Since “ACS” augmented the
circulating antibody titre, it was thought worthwhile to
evaluate its eﬀect eﬀect on CD19 +B cells, IL-4 and to
study the IgG1 and IgM response of the primary and the
secondary reponse of the immune system by Flowcytometry.
ACS showed signiﬁcant enhancing eﬀect of CD19+ B-
lymphocytes where approximately a two-fold increase was
observed, which was comparable to Levamisole. ACS highly
upregulated the expression of IL-4 cytokine, which is an
autocrine growth and diﬀerentiation factor for Th2 cells,
the increase in IL-4 level was highly comparable to the IL-4
secretions of Levamisole. Furthermore, the results presented
herein show that ACS treatment increased two to three fold
the production of anti-SRBC IgG and IgM lymphocytes8 Evidence-Based Complementary and Alternative Medicine
from immunized mice when measured by ﬂowcytometry
(Figure 9).
The result suggests that the oral administration of ACS
drives a shift in Th1:Th2 balance toward Th2-dominant
immunity by increased IL-4 cytokine expression levels rather
than Th1 reponse. Levamisole up regulated Th1 as well as
Th2 cytokines (Figures 7 and 8).
5. Conclusion
In conclusion, this study suggests that even complex botan-
ical mixtures can exhibit selectivity in immune therapy and
willbe usefultounderline importance ofsystemsapproaches
in the ethnopharmacology based drug discovery [35, 36].
This ﬁndings outlined above establish Th2 upregulating
activity of ACS and suggests its use in conditions where
Th1/Th2 modulation is required and thus is suggestive of its
possibletherapeuticusefulness.Suchplantbasedmodulators
may have applications in the treatment of immunodeﬁciency
diseases, allergic manifestations, and for combinational ther-
apy with antibiotics and as vaccine adjuvants. Its apparent
safety over long-term administration is encouraging enough
to warrant further studies to explore its possible therapeutic
role in modern clinical practice.
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